Application for COVID-19 vaccine Nuvaxovid against Omicron variant XBB.1.5 withdrawn

18 December 2023 - The manufacturer Novavax is no longer pursuing marketing authorisation for its COVID-19 vaccine in Switzerland. ...

Read more →

Swissmedic approves Moderna coronavirus vaccine Spikevax XBB.1.5

28 September 2023 - Spikevax XBB.1.5 approved for persons aged 18 and over ...

Read more →

Moderna submits authorisation application for coronavirus vaccine Spikevax XBB.1.5

13 July  2023 - Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5 ...

Read more →

Moderna announces global regulatory submissions for its respiratory syncytial virus (RSV) vaccine, mRNA-1345

5 July 2023 - Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, ...

Read more →

Swissmedic issues unlimited authorisation for booster dose of Moderna's bivalent COVID-19 Original/Omicron BA.4-5 vaccine

8 March 2023 - Spikevax bivalent Original/Omicron BA.4-5 mRNA vaccine authorised for people aged 18 and over. ...

Read more →

Moderna applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine

18 November 2022 - Application submitted for Spikevax Bivalent Original / Omicron BA.4-5 (mRNA-1273.222) ...

Read more →

Swiss drugs regulator approves one of Pfizer's COVID-19 booster shots

10 October 2022 - Swiss drugs regulator Swissmedic said on Monday it had temporarily approved Pfizer's COVID-19 booster shot targeting ...

Read more →

Pfizer applies to Swissmedic for authorisation of another COVID-19 vaccine

22 September 2022 - Pfizer said on Thursday it had submitted an application to Swissmedic for authorisation of a further ...

Read more →

Swissmedic authorizes Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in adults aged 18 and older

5 September 2022 - Novavax, today announced that Swissmedic has expanded its temporary authorisation of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in Switzerland ...

Read more →

Swissmedic authorises Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in adults aged 18 and older

2 September 2022 - Novavax today announced that Swissmedic has expanded its temporary authorisation of Nuvaxovid COVID-19 vaccine in Switzerland for ...

Read more →

Swissmedic authorises Moderna's Omicron targeting bivalent booster candidate MRNA-1273.214

29 August 2022 - Switzerland becomes among the first countries in the world to approve the use of a next-generation ...

Read more →

Novavax files in Switzerland for expanded conditional marketing authorisation of Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in individuals aged 18 and over

7 July 2022 - Novavax today announced the submission of a request to Swissmedic to expand the conditional marketing authorisation ...

Read more →

Swissmedic grants conditional marketing authorisation for Novavax COVID-19 vaccine

13 April 2022 - Nuvaxovid is the first protein-based COVID-19 vaccine authorised for use in Switzerland. ...

Read more →

Switzerland approves its first protein-based Covid vaccine

15 April 2022 - Swissmedic announced its approval on Wednesday making Nuvaxovid the first protein-based vaccine to be licensed in Switzerland.  ...

Read more →

Novavax files for conditional marketing authorisation of COVID-19 Vaccine in Switzerland

14 February 2022 - Novavax today announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional marketing authorisation ...

Read more →